A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Hydrogen peroxide (Primary)
  • Indications Seborrhoeic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 01 Jun 2018 Results of two identical studies (NCT02667236 and NCT02667275) assessing the safety and efficacy of hydrogen peroxide topical solution, 40%, published in the Journal of the American Academy of Dermatology
    • 16 May 2018 According to an Aclaris Therapeutics media release, data will be presented at the International Investigative Dermatology (IID) 2018 Meeting.
    • 08 Feb 2018 According to an Aclaris Therapeutics media release, data will be presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top